Evidence map›Paper›PMID 36505816›Full record

ArticleFrontiers in oncology2022

Skin cancer outcomes and risk factors in renal transplant recipients: Analysis of organ procurement and transplantation network data from 2000 to 2021.

Xiaowei Hao, Wenhui Lai, Xinze Xia, Junnan Xu, Yangyang Wu, Chao Lv, Qingyang Meng, Kaikai Lv, Shuai Huang, Zhenjun Luo and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Xiaowei HaoDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing, China.
Wenhui LaiDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing, China.
Xinze XiaDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing, China.
Junnan XuDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing, China.
Yangyang WuDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing, China.
Chao LvDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing, China.
Qingyang MengDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing, China.
Kaikai LvDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing, China.
Shuai HuangDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing, China.
Zhenjun LuoDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing, China.
Jun DongDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing, China.
Qing YuanDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing, China.
Chinese PLA General Hospital · CNHebei North University · CNPeople's Liberation Army 401 Hospital · CNWeifang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Posttransplant skin cancer is the most common malignancy after patients have undergone renal transplantation. Through comprehensive observation with a large sample size nationwide, understanding the risk factors and outcome of posttransplant skin cancer will help to develop appropriate patient surveillance and disease prevention strategies. Materials and methods: This retrospective population-based cohort study was based on Organ Procurement and Transplantation Network data released in March 2021. Characteristics and outcomes, including patient survival and graft survival of recipients, were compared. Risk factors for posttransplant skin cancer, cancer onset momentum, and mortality were determined. Results: A total of 199,564 renal transplant recipients were included. After renal transplantation, 7,334 (3.68%), 6,093 (3.05%), and 936 (0.47%) were diagnosed with squamous cell carcinoma, basal cell carcinoma, and melanoma, respectively. Skin cancer was the major cause of death (squamous cell carcinoma: 23.8%, basal cell carcinoma: 18%, and melanoma: 41.6%). Five-year survival rates ranked from best to worst were as follows: basal cell carcinoma (96.7 [95% confidence interval: 96.3-97.2]%), squamous cell carcinoma (94.1 [93.5-94.6]%), melanoma (89.7 [87.7-91.6]%), and cancer-free (87.4 [87.2-87.5]%) ( Conclusion: Although posttransplant skin cancer is a major cause of recipient death, information regarding its impact on patient and graft survival is limited. Given the differences regarding risk factors for posttransplant skin cancer incidence, onset momentum, and mortality, personalized approaches to screening may be appropriate to address the complex issues encountered by kidney transplant recipients.

Indexed as

end stage renal disease (ESRD)renal transplantation (RT)risk factorsskin cancerUNOS/OPTN

Identifiers

PMID36505816
PMCPMC9731355
OpenAlexW4309905722

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.